Please assess the completion status of the following clinical trial:

Trial Title: Hormone Treatment in Growth Hormone and Testosterone Deficient Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Group 1:~1. Age~2. F/M~3. Stable phase after TBI, SAH or IS~4. Stable substitution of other hormonal axes~5. GH below 6 ng/ml after stimulation with ITT or GH below cut-off in GHRH/arginine test using BMI-adjusted cut-off limits, GHRH/arginine test should be done only in patients denying or with a contraindication for ITT~6. Written informed consent~Group 2:~1. Age~2. M~3. PSA in normal range~4. Stable phase after TBI, SAH or IS~5. Stable substitution of other hormonal axes~6. Below 3.5 ng/ml testosterone~7. Written informed consent~Group 3:~1. Age~2. F/M~3. Stable phase after TBI, SAH or IS~4. GH higher 6 ng/ml after stimulation with ITT or GH below cut-off in GHRH/arginine test using BMI-adjusted cut-off limits, GHRH/arginine test should be done only in patients denying or with a contraindication for ITT~5. Written informed consent~Exclusion Criteria:~Group 1:~1. Pregnancy/lactation period~2. Women of childbearing potential not using an adequate method of birth control~3. Men not willing to use an adequate method of birth control~4. Previous or concomitant medication with GH~5. Hypersensitivity to GH~6. Drug or alcohol abuse~7. Condition which in opinion of investigator makes patient unsuitable for inclusion~8. Participation in another clinical trial with investigational new drug~9. Planned treatment or changes in established treatment with other drug which might significantly influence GH axis or cognitive function~10. Non-ability to perform testing~11. Presence of other conditions listed in contraindications or warnings in local SPC of GH~12. Onset of GH-deficiency before BI~Group 2:~1. Men not willing to use an adequate method of birth control~2. Previous or concomitant medication with androgens or anabolic steroids within 12 months~3. Hypersensitivity to active substances or excipients of Nebido®~4. Drug or alcohol abuse~5. Condition which in opinion of investigator makes patient unsuitable for inclusion~6. Participation in another clinical trial with investigational new drug~7. Planned treatment or changes in established treatment with other drug which might influence gonadotrophic axis or cognitive function~8. Severe disturbances in articulation, visual faculty, hearing~9. Presence of other conditions listed in contraindications or warnings in local SPC of Nebido®~10. Onset of hormonal deficiency before BI~11. Suspicion or known history of prostate or breast cancer or other hormone dependent neo plasia as well as history of malignancy within last 5 years~12. Abnormal finding on DRE~13. PSA higher 4 ng/ml~14. History of clinically significant post void residual urine before BI~15. Suspicion or known history of liver tumor~16. Blood coagulation irregularities presenting an increased risk of bleeding after i.m injections~17. Hypercalcemia accompanying malignant tumors~18. Sleep apnea~19. Polycythemia~20. Haematocrit higher than 50 %~21. Concurrent use of DHEA, anabolic steroids, clomipramine, antiandrogens, estrogen, ACTH, corticosteroids, oxyphenbutazone~22. Uncontrolled thyroid disorders like diabetes mellitus, epilepsia, migraine, hypertension, coronary heart disease as well as hepatic, renal or cardiac insufficiency~23. Patients requiring or undergoing fertility treatment~24. Condition which in opinion of investigator makes patient unsuitable for inclusion~25. Non-ability to perform cognitive testing~26. Onset of androgen deficiency before BI.~Group 3:~1. Previous or concomitant medication with androgens, GH or anabolic steroids within 12 months~2. Drug or alcohol abuse~3. Condition which in opinion of investigator makes patient unsuitable for inclusion~4. Participation in another clinical trial with investigational new drug~5. Planned treatment or changes in established treatment with other drug which might influence gonadotrophic axis or cognitive function~6. Severe disturbances in articulation, visual faculty, hearing~7. Non-ability to perform cognitive testing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Genotropin (Type: ACTIVE_COMPARATOR): 6 months Genotropin (open treatment)~Daily dose:~Male \< 45 years: 0,4 mg; ≥ 45 years: 0,2 mg Female \< 45 years: 0,5 mg; ≥ 45 years: 0,3 mg Starting with half of the dose for the first 4 weeks.
- Testosterone undecannoate (Type: ACTIVE_COMPARATOR): 18 weeks testosterone undecanoate/placebo (double-blind treatment) 1000 mg/4 ml at baseline and after 6 weeks
- control group (Type: NO_INTERVENTION): No Intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).